Total Saponin from Korean Red Ginseng Inhibits Thromboxane A₂ Production Associated Microsomal Enzyme Activity in Platelets

Dong-Ha Lee¹†, Hyun-Jeong Cho²†, Hye-Yeon Kang³, Man Hee Rhee³, and Hwa-Jin Park¹*

¹Department of Biomedical Laboratory Science, College of Biomedical Science and Engineering and Regional Research Center, Inje University, Gimhae 621-749, Korea
²Department of Biomedical Laboratory Science, College of Medical Science, Konyang University, Daejeon 302-718, Korea
³Laboratory of Veterinary Physiology & Signaling, College of Veterinary Medicine, Kyungpook National University, Daegu 702-701, Korea

Ginseng, the root of Panax ginseng Meyer, has been used frequently in traditional oriental medicine and is popular globally. Ginsenosides, which are the saponins in ginseng, are the major components having pharmacological and biological activities, including anti-diabetic and anti-tumor activities. In this study, we investigated the effects of total saponin from Korean red ginseng (TSKRG) on thrombin-produced thromboxane A₂ (TXA₂), an aggregating thrombogenic molecule, and its associated microsomal enzymes cyclooxygenase (COX)-1 and TXA₂ synthase (TXAS). Thrombin (0.5 U/mL) increased TXA₂ production up to 169 ng/10⁸ platelets as compared with control (0.2 ng/10⁸ platelets). However, TSKRG inhibited potently TXA₂ production to the control level in a dose-dependent manner, which was associated with the strong inhibition of COX-1 and TXAS activities in platelet microsomes having cytochrome c reductase activity. The results demonstrate TSKRG is a beneficial traditional oriental medicine in platelet-mediated thrombotic diseases via suppression of COX-1 and TXAS to inhibit production of TXA₂.

Keywords: Total saponin from Korean red ginseng, Cyclooxygenase 1, Thromboxane A₂ synthase

INTRODUCTION

Platelet aggregation is essential for normal hemostatic process when blood vessels are injured. However, it can also cause cardiovascular diseases such as thrombosis, atherosclerosis and myocardial infarction [1]. Hence, inhibition of platelet aggregation might be a promising target to the development of anti-thrombotic drugs and an approach for the prevention of cardiovascular disease. When platelets are activated by agonists such as collagen, thrombin and adenosine diphosphate (ADP), phosphatidylinositol 4, 5-bisphosphate (PIP₂) is broken down by phospholipase C which is activated through G-protein coupled receptor (GPCR) or glycoprotein VI. Diacylglycerol (DG) and inositol-1,4,5-trisphosphate (IP₃) are generated from PIP₂ [2,3]. IP₃ mobilizes Ca²⁺ from the dense tubular system into the cytoplasm. Ca²⁺ calmodulin complex activates myosin light chain kinase, which in turn phosphorylates the myosin light chain [4,5]. Moreover, DG phosphorylates pleckstrin through protein kinase C (PKC) and it is also used as a donor of arachidonic acid (AA) [6]. AA is a precursor of prosta-glandin G₂/prostaglandin H₂ (PGH₂) and thromboxane A₂ (TXA₂) [7]. TXA₂ interacts with membrane receptors of other platelets in a autacoidal reaction, which results in elevation of intracellular free Ca²⁺, a platelet aggregation-
inducing molecule, via G\textsubscript{q} of GPCR [3, 8, 9]. Inhibition of TXA\textsubscript{2} production leads to anti-thrombosis. Anti-thrombotic drugs such as aspirin, imidazole and indomethacin have anti-thrombotic effects by inhibiting the generation of TXA\textsubscript{2}. The mechanisms are concerned with cyclooxygenase (COX)-1 and TXA\textsubscript{2} synthase (TXAS), which convert AA to TXA\textsubscript{2} [10, 11]. Therefore, the inhibition of COX-1 and TXAS is very important to prevent platelet-induced thrombosis. For instance, aspirin, COX-1 inhibitor, and ozagrel, TXAS inhibitor are being used as anti-thrombotic agents [12, 13].

It has been reported that nonsaponin fraction [14-16], aqueous fraction [17], polyacetylene compound [18], acidic polysaccharide [19], panaxatriol and panaxadiol [20-22], ginsenoside R\textsubscript{g1} [17, 23], and dihydroginsenoside R\textsubscript{g3} [24] from Panax ginseng have anti-platelet effects on agonist-induced platelet aggregation. However, there are no reports concerning the involvement of ginseng compounds in the inhibition of COX-1 or TXAS to suppress platelet aggregation. In this study, we investigated whether total saponin from Korean red ginseng (TSKRG) inhibits the specific activities of COX-1 and TXAS to suppress TXA\textsubscript{2} production, and this provide new information of TSKRG-mediated anti-platelet activity.

### MATERIALS AND METHODS

#### Materials

Total saponin from Korean red ginseng was obtained from KT&G Central Research Institute (Daejeon, Korea). Thrombin was purchased from Chrono-Log Corporation (Havertown, PA, USA). TXB\textsubscript{2} enzyme immunoassay kits were purchased from GE Healthcare (Buckinghamshire, UK). COX-fluorescent activity assay kit, ozagrel and prostaglandin H\textsubscript{2} were purchased from Cayman Chemical (Ann Arbor, MI, USA). Cytochrome c reductase (NADPH) assay kit and other reagents were obtained Sigma-Aldrich (St. Louis, MO, USA). All other chemicals and reagents used in the present study were of analytical grade.

#### Preparation of washed rat platelets

Whole blood was obtained from the abdominal vein of normal Sprague-Dawley rats (150-200 g), anti-coagulated with 0.38% sodium citrate solution and centrifuged at 220 \(\times\) g for 10 min to obtain the platelet-rich plasma. After removing the red blood cells, the preparation was centrifuged again at 1650 \(\times\) g for 10 min to obtain platelet pellets. The platelets were washed twice with a washing buffer (138 mM NaCl, 2.7 mM KCl, 12 mM NaHCO\textsubscript{3}, 0.36 mM NaH\textsubscript{2}PO\textsubscript{4}, 5.5 mM glucose, 1 mM EDTA, pH 6.5). Washed platelets were suspended in a buffer consisting of 138 mM NaCl, 2.7 mM KCl, 12 mM NaHCO\textsubscript{3}, 0.36 mM NaH\textsubscript{2}PO\textsubscript{4}, 5.5 mM glucose, 0.49 mM MgCl\textsubscript{2} and 0.25% gelatin, pH 7.4, and adjusted to a final concentration of 5\times10\textsuperscript{8} platelets/mL. All of the procedures were carried out at room temperature (25°C) to avoid platelet aggregation from cooling [25]. Animals were maintained as per the principles and guidelines of the Ethics Committee of the Animal Care of Inje University.

#### Measurement of platelet aggregation

The washed platelets (10\textsuperscript{8}/mL) were pre-incubated at 37°C in the presence of 2 mM CaCl\textsubscript{2} with or without TSKRG. After 3 min, platelets were further stimulated with thrombin (0.5 U/mL) for 5 min. The aggregation was monitored using an aggregometer (Chrono-Log Corporation) with gentle stirring. Each aggregation rate was calculated as a percent of light transmission. The suspending buffer was used as a reference (transmission 0). TSKRG was dissolved in water; this had no effect on the results.

#### Measurement of thromboxane B\textsubscript{2}

Because TXA\textsubscript{2} is unstable and quickly converted to thromboxane B\textsubscript{2} (TXB\textsubscript{2}), the amounts of TXA\textsubscript{2} were evaluated by determining TXB\textsubscript{2} [7]. Washed platelets (10\textsuperscript{8}/mL) were pre-incubated at 37°C in the presence of 2 mM CaCl\textsubscript{2} with or without TSKRG or other reagents. After 3 min, platelets were further stimulated with thrombin (0.5 U/mL) for 5 min. The reaction was terminated by adding ice-cold 5 mM EDTA and 0.2 mM indomethacin to inhibit subsequent metabolism of AA to TXA\textsubscript{2}. The amounts of TXB\textsubscript{2}, a stable metabolite of TXA\textsubscript{2}, were determined using a TXB\textsubscript{2} EIA kit according to the procedure described by the manufacturer. The assay is based on the competition between unlabelled TXB\textsubscript{2} and a fixed quantity of peroxidase-labelled TXB\textsubscript{2} for a limited number of binding sites on a TXB\textsubscript{2} specific antibody.

#### Isolation of microsomal fraction

Washed platelets (10\textsuperscript{8} platelets/mL) in suspending buffer (pH 7.4) containing 1% protease inhibitor were sonicated once at a sensitivity of 100% for 20 s and 10 times on ice with a model HD2070 sonicator (Bandelin Electronic, Bandelin, Germany) to obtain platelet lysates. Each homogenate was ultracentrifuged at 105,000 \(\times\) g for 1 h at 4°C to obtain a microsomal fraction containing endoplasmic reticulum (ER) membrane. The supernatant was considered as a cytosolic fraction. All of the separat-
ed fractions were identified by cytochrome c reductase (an ER membrane marker enzyme) [26] and used as enzyme source in Western blots as described below.

**Cytochrome c reductase activity assay**

Cytochrome c reductase is a flavoprotein localized in the ER. Cytochrome c reductase activity of the fractions (homogenates, cytosols and microsomes of platelets) was assayed using a cytochrome c reductase (NADPH) assay kit (Sigma-Aldrich). The reaction was initiated by addition of NADH and the reduction of cytochrome c was monitored by the increase of absorbance at 550 nm for 7 min with a kinetic program.

**Western blot analysis**

Protein concentrations were measured using the Bradford method. Protein samples (30 µg) from each treatment platelets were separated by 8% sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The separated proteins were electrophoretically transferred to a polyvinylidene fluoride membrane (GE Healthcare, Franklin Lakes, NJ, USA). An immunoblot was prepared using primary antibody (COX-1, 1:200 dilution; TXAS, 1:1000 dilution) and alkaline phosphatase-conjugated secondary antibody at a dilution of 1:10,000 (Santa Cruz Biotechnology, Santa Cruz, CA, USA). After treatment with secondary antibody (anti-mouse of anti-goat IgG-horseradish peroxidase conjugate), detection of antibody-bound protein in the membrane was performed by enhanced chemiluminescence (GE Healthcare, Buckinghamshire, UK).

**Cyclooxygenase-1 activity assay**

For the measurement of COX-1 activity, the microsomal fraction of platelets was pre-incubated with aspirin (500 µM), a positive control as a COX inhibitor, with or without various concentrations of TSKRG at 37°C for 30 min. COX-1 activity of the treated microsomal fraction was assayed with COX-1 fluorescent assay kit (Cayman Chemical).

**Thromboxane A₂ synthase activity**

For the measurement of TXAS activity, the microsomal fraction was preincubated with ozagrel (11 nM, IC₅₀), a positive control as a TXAS inhibitor, with or without various concentrations of TSKRG at 37°C for 5 min. The reaction was initiated by the addition of PGH₂. After incubation for 1 min at 37°C, the reaction was terminated by the addition of 1 M citric acid. After neutralization with 1 N NaOH, the amount of TXB₂, a stable metabolite of TXA₂, was determined using a TXB₂ enzyme immunoassay kit according to the procedure described by the manufacturer.

**Statistical analyses**

The experimental results are expressed as the mean±SEM, accompanied by the number of observations. Data were assessed by analysis of variance. If this analysis indicated significant differences among the group means, then each group was compared by the Newman-Keuls method. A p-value <0.05 was considered statistically significant.

**RESULTS**

**Threshold concentration of thrombin causing platelet aggregation in a maximum**

When washed platelets (10⁸ platelets/mL) were incubated with various concentrations of thrombin, light transmission (%) indicating platelet aggregation was maximally increased by 0.25 U/mL of thrombin (Fig. 1). However, we used the 0.5 U/mL of thrombin.

**Effect of total saponin from Korean red ginseng on thromboxane A₂ production**

The amount of TXA₂ (determined as TXB₂) in intact platelets was 0.2 ng/10⁸ platelets, which was markedly increased to 33.93±1.22 ng/10⁸ platelets when platelets were stimulated with thrombin (0.5 U/mL). TSKRG (50-150 µg/mL), however, powerfully reduced the production of TXA₂ (Fig. 2). These results show that TSKRG may inhibit the activity of COX-1 or TXAS in a dose-dependent manner to suppress the production of TXA₂ in thrombin-induced platelet aggregation.

**Determination of enzyme source of cyclooxygenase-1 and thromboxane A₂ synthase**

To determine whether TSKRG is involved in the inhibition of COX-1 and TXAS, enzyme sources having COX-1 or TXAS were needed. We measured the activity of cytochrome c reductase, an ER marker enzyme, in homogenates, microsomes and cytosols of platelets. As shown in Fig. 3A, the microsomal fraction had the highest specific activity of cytochrome c reductase. Next, we determined the fraction from platelets that expressed COX-1 and TXAS. Remarkably high expressions of COX-1 (70 kDa) and TXAS (58 kDa) were observed in the microsomal fraction (Fig. 3B). These observations were consistent with the view that the microsomal fraction from platelets had the highest activity of cytochrome
c reductase. Thus, microsomal fractions were used to determine the activities of COX-1 and TXAS.

**Effect of total saponin from Korean red ginseng on cyclooxygenase-1 activity**

COX-1 converts AA to PGH$_2$. To determine if the inhibitory effect of TSKRG on TXA$_2$ production was due to the direct suppression of COX-1, a cell-free enzyme assay method with the microsomal fraction of platelets was used. As shown in Fig. 4A, COX-1 activity in the absence of TSKRG (control) was 900.7±40.7 pmol/min/mg protein. However, TSKRG produced dose-dependent inhibition of COX-1 activity; at 150 µg/mL, COX-1 activity was reduced to 397.0±11.5 pmol/min/mg protein. As a positive control, 500 µM of aspirin was used, which inhibited COX-1 activity to 340.1±31.1 nmol/min/mg protein (Fig. 4A). The 56% inhibition by 150 µg/mL TSKRG as compared with that of control (900.7±40.07 pmol/min/mg protein) was almost equal to the 62% inhibition elicited by 500 µM of aspirin.

**Effect of total saponin from Korean red ginseng on thromboxane A$_2$ synthase activity**

To determine whether the inhibitory effect on TXA$_2$ production of TSKRG was due to the direct suppression of TXAS, the aforementioned cell-free enzyme assay...
method with the microsomal fraction of platelets was also used. In the TSKRG-untreated control, TXAS activity was 112.1±0.7 ng/min/mg protein. However, TSKRG inhibited TXAS activity in a dose-dependent fashion, to 39.6±0.3 ng/min/mg protein at 150 µg/mL. In addition, 11 nM ozagrel as a positive control was used; TXAS activity was 17.5±0.9 ng/min/mg protein (Fig. 4B). The 64.7% inhibition by 150 µg/mL TSKRG as compared with 112.1±0.7 ng/min/mg protein of the control (approximately 77%) to that (84.4%) by 11 nM of ozagrel.

DISCUSSION

TXA₂ acts as a positive feedback promoter on activated platelets and is a strong agonist on resting platelets [3,27]. TXA₂ is also a vasoconstrictor and a bronchoconstrictor [28]. Thus, a compound that can inhibit TXA₂ action or production has potential application as an antithrombotic agent [29,30]. Because ginsenosides from P. ginseng do not inhibit TXA₂ production in collagen-, ADP-, and AA-activated platelets [31], we investigated if TSKRG containing ginsenosides lacked inhibitory activity on agonist-produced TXA₂. TSKRG decreased thrombin-elevated TXA₂ level in a dose-dependent manner (Fig. 2), which is consistent with the report that panaxadial and panaxatriol inhibitor of thrombin- or adrenaline-induced TXA₂ production [21,22].

Although these results indicate that TSKRG inhibits a pathway involved in TXA₂ production, it is insufficient for a complete understanding of the inhibitory action of ginseng compounds on platelet aggregation. Presently, we tried to explain the inhibitory mechanism of TSKRG on TXA₂-production by assaying the activities of the TXA₂ production-associated microsomal enzymes, COX-1 and TXAS. Because COX-1 and TXAS are localized in the endoplasmic reticulum [32,33], we isolated microsomes from platelets, determined its marker enzyme, cytochrome c reductase, and observed the expression of COX-1 and TXAS. The activity of cytochrome c reductase was highest in the microsomal fraction rather than the cytosolic fraction or homogenates (Fig. 3A). The results mean that the microsomal fractions from platelet lysates contain COX-1 and TXAS.

As shown in Fig. 3B, COX-1 (70 kDa) and TXAS (50 kDa) were potently expressed in the microsomal fraction than in other cellular fractions. We determined the effects of TSKRG on the activities of COX-1 and TXAS in the microsomal fraction. TSKRG inhibited COX-1 and TXAS activities. In the TSKRG-untreated control, COX-1 activity was 900.7±40.7 pmol/min/mg protein. But, activity was decreased in the presence of TSKRG to 340.1±11.5 pmol/min/mg protein. As a positive control, 500 µM aspirin also inhibited COX-1 activity to 300.1±31.1 pmol/min/mg protein (Fig. 4A). These results suggest that TSKRG may be used as a COX-1 inhibitor with aspirin. In addition, TXAS activity in the absence of TSKRG was 112.1±0.7 ng/min/mg protein (Fig. 4B),
while TSKRG inhibited TXAS activity to 39.6±0.3 ng/min/mg protein. As a positive control, 11 nM ozagrel also inhibited TXAS activity to 17.5±0.9 ng/min/mg protein. TSKRG may be used as a TXAS inhibitor, similar to ozagrel. TSKRG that we used contained ginsenoside (G)-Rg1, G-Re, G-Rb1, G-Rc, G-Rg2, G-Rb2, G-Rd, and G-Rg3, which were analyzed with HPLC-ELSD method (Zorbax ODS C18 guard column [250×4.6 mm id, 5 μm], Zorbax ODS C18 column [12.5×4.6 mm id, 5 μm]). Unfortunately, in the present study, we don’t know which ginsenoside of TSKRG has inhibitory effect on thrombin-stimulated COX-1 and TXAS activities, these should be investigated in the future.

Thrombin is a strong stimulator of platelet aggregation, and activates phospholipase C via protease-activated receptors (PARs)-1 and PAR-4 of GPCR, which supplies TXA2 precursor AA from phosphoinositides such as PIP2, phosphatidylinositol 4-monophosphate (PIP), and phosphatidylinositol (PI) [3,34]. Accordingly, it cannot not excluded that TSKRG could inhibit phospholipase C activity to suppress the thrombin-mediated hydrolysis of phosphoinositides such as PI, PIP, and PI, It can be inferred that panaxatriol from Panax ginseng inhibited the thrombin-stimulated hydrolysis of PIP2, PIP, and PI [20]. At present, although ginsenoside Rg1, ginsenoside Rg3, and dihydroginsenoside Rg5, are known to have an anti-platelet effect [17,23,24,35], we are unable to discern which TSKRG ginsenoside is involved in the inhibition of COX-1 or TXAS activities to suppress TXA2 production. Hepoixilin cyclopropane, which inhibits TXA2 production by suppressing TXAS activity, inhibits the binding of TXA2 to the TXA2 receptor (TP) [36]. TXA2 is a platelet agonist that binds to TP linked to both Gαq and G12/G13 of GPCR [3]. Gq-stimulated phospholipase C6 hydrolyses PIP2, PIP, and PI, which produces IP3 that in turn mobilizes Ca2+ and DG to activate PKC. These signaling pathways are involved in facilitating platelet aggregation. G12/G13 mediates the small GTPase Rho/Rho-kinase, which stimulates phosphorylation of myosin light chain to fully activate platelet aggregation and degranulation [37]. Considering previous reports [3,36,37], TXAS synthase activity inhibition by TSKRG may be involve in the down-regulation of Gq and G12/G13-mediated platelet aggregation pathway. In addition, spinach saponin and hepoixilin cyclopropane that inhibit TXA2 production increase cyclic adenosine monophosphate (cAMP) [36,38], which suppresses cytosolic free Ca2+, an aggregation-inducing molecule. Because TSKRG inhibits TXA2 production as well as spinach saponin and hepoixilin cyclopropane, TSKRG may be involved in increasing the production of cAMP. In conclusion, TSKRG has a beneficial anti-platelet effect within thrombotic diseases via the inhibition of COX-1 and TXAS activities.

ACKNOWLEDGEMENTS

This study was supported by a grant (20110233 to PHJ) from the National Research Foundation, and supported in part by a grant (2010-0024028) from Basic Science Research Program through the National Research Foundation funded by the Ministry of Education, Science and Technology, Korea, and supported in part by grant (20100420) from Inje University, Korea.

REFERENCES

1. Schwartz SM, Heimark RL, Majesky MW. Developmental mechanisms underlying pathology of arteries. Physiol Rev 1990;70:1177-1209.
2. Berridge MJ, Irvine RF. Inositol trisphosphate, a novel second messenger in cellular signal transduction. Nature 1984;312:315-321.
3. Jennings LK. Role of platelets in atherothrombosis. Am J Cardiol 2009;103(3 Suppl):4A-10A.
4. Pasqui AL, Capecchi PL, Ceccatelli L, Mazza S, Gistri A, Laghi Pasini F, Di Perri T. Nitroprusside in vitro inhibits platelet aggregation and intracellular calcium translocation. Effect of haemoglobin. Thromb Res 1991,61:113-122.
5. Nishikawa M, Tanaka T, Hidaka H. Ca2+-calmodulin-dependent phosphorylation and platelet secretion. Nature 1980;287:863-865.
6. Murakami K, Chan SY, Routtenberg A. Protein kinase C activation by cis-fatty acid in the absence of Ca2+ and phospholipids. J Biol Chem 1986;261:15424-15429.
7. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A 1975;72:2994-2998.
8. Cattaneo M, Tenconi PM, Cecchi A, Mannucci PM. In vitro effects of picotamide on human platelet aggregration, the release reaction and thromboxane B2 production. Thromb Res 1991;62:717-724.
9. Moriyama T, Takamura H, Narita H, Tanaka K, Matsuura T, Kito M. Elevation of cytosolic free Ca2+ is directly evoked by thromboxane A2 in human platelets during activation with collagen. J Biochem 1988;103:901-902.
10. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994;330:1287-1294.
vano R, Cuccurullo F, Patrono C, Rebuzzi AG, Liuzzo G, Quaranta G et al. Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. Circulation 1997;96:1109-1116.

12. Patrono C. Aspirin: new cardiovascular uses for an old drug. Am J Med 2001;110:62S-65S.

13. Ichikawa K, Tazawa S, Hamano S, Kojima M, Hiraku S. Effect of ozagrel on locomotor and motor coordination after transient cerebral ischemia in experimental animal models. Pharmacology 1999;59:257-265.

14. Park HJ, Lee JH, Song YB, Park KH. Effects of dietary supplementation of lipophilic fraction from Panax ginseng on cGMP and cAMP in rat platelets and on blood coagulation. Biol Pharm Bull 1996;19:1434-1439.

15. Park HJ, Rhee MH, Park KM, Nam KY, Park KH. Effect of non-saponin fraction from Panax ginseng on cGMP and thromboxane A2 in human platelet aggregation. J Ethnopharmacol 1995;49:157-162.

16. Rhee MH, Park KM, Park HJ, Nam KY, Park KH. Inhibition of serotonin release by lipophilic fraction from Korean red ginseng. Korean J Ginseng Sci 1993;17:127-130.

17. Park HJ, No YH, Rhee MH, Park KM, Park KH. Effects of protein fractions and ginsenosides from Panax ginseng C.A. Meyer on substrate phosphorylation by a catalytic fragment of protein kinase. Korean Biochem J 1994;27:280-283.

18. Kuo SC, Teng CM, Lee JC, Ko FN, Chen SC, Wu TS. Antiplatelet components in Panax ginseng. Planta Med 1990;56:164-167.

19. Lee WM, Kamruzzaman SM, Song YB, Cho JY, Park HJ, Rhee MH. Inhibitory activities of red ginseng acidic polysaccharide in platelet aggregation. J Ginseng Res 2008;32:73-78.

20. Park JM, Rhee MH, Shin HJ, Song YB, Hyun HC, Park KH, Cho HJ, Choi SA, Kang HC, Kim KJ et al. Inhibitory effects of Panaxatriol from Panax ginseng C.A. Meyer on phosphoinositide breakdown induced by thrombin in platelets. J Ginseng Res 2008;32:107-113.

21. Park KM, Rhee MH, Park HJ. Panaxadiol and panaxatriol from Panax ginseng C.A. Meyer inhibit the synthesis of thromboxane A2 in adrenaline-stimulated human platelet aggregation. Korean J Ginseng Sci 1994;18:44-48.

22. Park HJ, Rhee MH, Park KM, Nam KY, Park KH. Panaxadiol from Panax ginseng C.A. Meyer inhibits synthesis of thromboxane A2 in platelet aggregation induced by thrombin. Korean J Ginseng Sci 1993;17:131-134.

23. Kimura Y, Okuda H, Arichi S. Effects of various ginseng saponins on 5-hydroxytryptamine release and aggregation in human platelets. J Pharm Pharmacol 1988;40:838-843.

24. Lee WM, Kim SD, Park MH, Cho JY, Park HJ, Seo GS, Rhee MH. Inhibitory mechanisms of dihydroginsenoside Rg3 in platelet aggregation: critical roles of ERK2 and cAMP. J Pharm Pharmacol 2008;60:1531-1536.

25. Reuter H, Niemeyer G, Gross R. Studies of the aggregation of human blood platelets. 3. On the inhibition of platelet aggregation in EDTA plasma following incubation at 37 degrees C. Klin Wochenschr 1967;45:1147-1149.

26. Lagarde M, Menashi S, Crawford N. Localisation of phospholipase A2 and diglyceride lipase activities in human platelet intracellular membranes. FEBS Lett 1981;124:23-26.

27. Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002;8:1227-1234.

28. FitzGerald GA. Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. Am J Cardiol 1991;68:11B-15B.

29. Clutton P, Folts JD, Freedman JE. Pharmacological control of platelet function. Pharmacol Res 2001;44:255-264.

30. Halushka PV, Allan CJ, Davis-Bruno KL. Thromboxane A2 receptors. J Lipid Mediat Cell Signal 1995;12:361-378.

31. Teng CM, Kuo SC, Ko FN, Lee JC, Lee LG, Chen SC, Huang TF. Antiplatelet actions of panaxyanol and ginsenosides isolated from ginseng. Biochim Biophys Acta 1989;990:315-320.

32. Samuelsson B. Biosynthesis and metabolism of prostaglandins. Prog Biochem Pharmacol 1967;3:59-70.

33. Sun FF, Chapman JP, McGuire JC. Metabolism of prostaglandin endoperoxide in animal tissues. Prostaglandins 1977;14:1055-1074.

34. Savage B, Cattaneo M, Ruggeri ZM. Mechanisms of platelet aggregation. Curr Opin Hematol 2001;8:270-276.

35. Lee SR, Park HJ, Choi KJ, Kim ND. Inhibitory effects of ginsenoside Rg3 on platelet aggregation and its mechanism of action. Korean J Ginseng Sci 1997;21:132-140.

36. Pace-Asciak CR, Reynaud D, Demin P, Aslam R, Sun A. A new family of thromboxane receptor antagonists with secondary thromboxane synthase inhibition. J Pharmacol Exp Ther 2002;301:618-624.

37. Moers A, Wettschureck N, Offermanns S. G13-mediated signaling as a potential target for antiplatelet drugs. Drug News Perspect 2004;17:493-498.

38. Cho HJ, Choi SA, Kim CG, Hong JH, Park HJ, Park HJ. Dietary spinach saponin-enriched lipophilic fraction inhibits platelet aggregation and blood coagulation. J Med Food 2011;14:784-791.